Your session is about to expire
← Back to Search
This trial is studying TAK-500 to find out how well it works in treating adults with certain types of solid tumors that have spread or cannot be removed by surgery. TAK-500 will be given alone or with pembrolizumab and will be compared to standard of care.
- Kidney Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Pancreatic Cancer
- Liver Cancer
- Breast Cancer
- Stomach Cancer
- Esophageal Cancer
- Nasopharyngeal Cancer
- Squamous Cell Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 2 trial • 40 Patients • NCT03018080
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have been using e-cigarettes or vaping within the past 90 days before starting the study drug.You are currently a smoker.You have taken certain medications that affect the immune system in the past 6 months.You have been diagnosed with serious lung conditions such as pneumonitis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis. You also have severe pleural effusion (fluid around the lungs) that is not controlled by tapping or requires a catheter.You are using corticosteroids that are applied to the skin, nose, eyes, joints, or inhaled, but not taken by mouth or injected into your veins.You are taking a low dose of steroid medication to replace what your body doesn't make enough of. The dose should not be more than 10 mg of prednisone per day.You have been diagnosed with advanced or spread-out tumors in certain areas of your body, such as the stomach, pancreas, liver, lung, head and neck, breast, kidney, or nasopharynx. You have already tried all standard treatments for your type of cancer, and either the treatments did not work or you had side effects that made it impossible to continue with them.
- Group 1: Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 2)
- Group 2: Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA
- Group 3: Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 + Pembrolizumab (RDE 1)
- Group 4: Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA
- Group 5: Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 1)
- Group 6: Dose Escalation: TAK-500 Single Agent (SA)
- Group 7: Dose Expansion: 3L RCC: TAK-500 + Pembrolizumab (RDE 1)
- Group 8: Dose Escalation: TAK-500 + Pembrolizumab
- Group 9: Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How secure is the application of TAK-500 for human health?
"Due to the limited safety and efficacy data surrounding TAK-500, it received a score of 1."
In what geographic locations is this trial carrying out its research?
"Besides the University of Colorado - Anschutz Medical Campus - PPDS in Aurora, Dana Farber Cancer Institute in Boston, and Cancer Clinical Trials Office (CCTO) University of Colorado Anschutz Medical Campus in Denver, this trial is also recruiting patients from 8 other medical centres."
Is there still the opportunity to join this clinical exploration?
"According to clinicaltrials.gov, this medical trial is actively seeking participants after first being posted on April 26th 2022 and most recently updated on August 3rd of the same year."
For what medical conditions is TAK-500 commonly employed?
"TAK-500 is frequently utilized to treat malignancies. It can also be beneficial in the management of unresectable melanoma, microsatellite instability high, and as a response to chemotherapy failure."
How extensive is the scope of participants in this particular research study?
"In order to proceed with the clinical trial, a total of 106 qualified participants are required. The sponsor for this study, Takeda Pharmaceuticals, is recruiting patients from two sites - University of Colorado - Anschutz Medical Campus- PPDS in Aurora and Dana Farber Cancer Institute in Boston."
What other exploratory trials have been conducted with TAK-500?
"At the moment, there are 961 clinical trials for TAK-500. Of those active studies, 122 have progressed to Phase 3. Many of these experiments take place in Houston, Texas; however, it should be noted that 35731 sites around the world offer this medication as part of a research study."
Share this study with friends